Candida auris (C. auris) is a yeast, a type of fungus, which can cause infections in humans. Patients with a delayed diagnosis of C. … How does C. auris spread? Patients can carry C. auris somewhere on their body, even if it is not making them sick. Often, candidiasis is acquired in hospitals by patients with weakened immune systems. Candida auris is a recently emerged, human-pathogenic yeast causing nosocomial outbreaks all over the globe . Conventional laboratory techniques could lead to misidentification and inappropriate management, making it difficult to control the spread of C. auris in healthcare settings. Candida auris emerged as a pathogen resistant to multiple antifungal and has been associated with nosocomial outbreaks with high transmission capacity between hospitalized individuals.C. Infections have occurred primarily in patients who were already in the hospital for other reasons. This video is not going to make it any better. Retrospective review of Candida strain collections found that the earliest known strain of C. auris dates to 1996 in South Korea. C. auris will not make hyphae or pseudohyphae on cornmeal agar, unlike Candida guilliermondii, C. lusitaniae, and Candida parapsilosis, which are common misidentifications on the MicroScan.Unlike most Candida species excluding C. parapsilosis, C. auris will grow in high salt (10% NaCl) and at high temperature (40-42˚C). Based on information from a limited number of patients, 30–60% of people with C. auris infections have died. Overall, 59% patients died, including 68% with BSIs and 71% with urinary tract infections who most likely died from associated sepsis, according … Candida auris is an emerging multi-drug-resistant fungus that is rapidly spreading worldwide. However, sporadic outbreaks of C. parapsilosis infection have been reported for decades, including clusters of invasive candidiasis in neonatal intensive care units likely transmitted via healthcare workers’ hands.20-22 Recently, an emerging species called Candida auris has caused outbreaks of invasive infections around the world likely because of its ability to colonize patient skin and persist on healthcare surfaces. Centers for Disease Control and Prevention. Candida Auris is a drug resistant fungus that has a high mortality rate. “Of note,” the researchers say: 4 patients who died experienced persistent fungemia and despite 5 days of micafungin therapy, C. auris again grew in blood culture. People who travel to these countries to seek medical care or who are hospitalized there for a long time may have an increased risk for C. auris infection. Learn more about Candida species distribution. Eight of the patients with candidemia died. However, because people who develop invasive candidiasis are typically already sick with other medical conditions, it can be difficult to determine the proportion of deaths directly attributable to the infection. Despite its name, C. auris can also affect many other regions of the body and can cause invasive infections, including bloodstream infections and wound infections. Currently healthcare experts are divided on just how dangerous COVID-19 really is. Around the world, up to 60% of patients who get a C. auris infection have died. isolates. Abstract. Candida auris, a novel Candida species first reported in Japan in 2009, is an emerging pathogen that has been isolated on five continents ().There are separate clonal strains displaying distinct mechanisms of antifungal resistance. Candida auris accounted for two thirds of cases; case-fatality rate was high (60%). Candida auris is a fungal pathogen that recently emerged and rapidly spread around the globe. Some types of Candida are increasingly resistant to the first-line and second-line antifungal medications, such as fluconazole and the echinocandins (anidulafungin, caspofungin, and micafungin). As laboratories continue to look for this fungus, it is likely that more cases will be reported. Help me gather more info on it. However, not all of them develop life-threatening … Abstract: Candida auris is a pathogenic yeast causing outbreaks in intensive care units with high mortality rates. infections are a major cause of morbidity and mortality in critically ill patients. CDC considers C. auris an emerging pathogen because increasing numbers of infections have been identified in multiple countries since it was recognized. Candidemia is one of the most common bloodstream infections in the United States.1 During 2013–2017, the average incidence was approximately 9 per 100,000 people; however, this number varies substantially by geographic location and patient population. “Of note,” the researchers say: 4patients who died experienced persistent fungemia and despite 5days of micafungin therapy, C. auris again grew in blood culture. Identification of C. auris infections is often difficult, as it is commonly misidentified as other Candida species. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. C. auris in the Middle-East Furthermore, C. auris accounts for most Candida bloodstream isolates in several areas, from around 20% to up to 38% of patients [9,10]. We report finding 17 cases of C. auris infection that were originally misclassified but correctly identified 27.5 days later on average. In New Delhi, India, candidemia affected 15 critically ill coronavirus disease patients admitted to an intensive care unit during April–July 2020. Click here for a map of cases in the United States. auris was first described in 2009, after being isolated from the external ear canal discharge of a patient in Japan. Yes. It is unlikely that routine travel to countries with documented C. auris infections would increase the chance of someone getting sick from C. auris. One study estimated the mortality attributable to candidemia to be 19–24%. Patients with a delayed diagnosis of C. auris had a 30-day mortality rate of 35.2%. In this situation, multiple classes of antifungals at high doses may be required to treat the infection. Approximately 3% of C. glabrata isolates are resistant to echinocandins, but the percentage may be higher in some hospitals. Transmission characteristics, interventions, patient outcomes and cost of resources are described. CDC and partners continue to work closely; click here for the latest information on Candida auris. CDC twenty four seven. After witnessing an unprecedented death rate due to the coronavirus spread, the United States is now struggling with a fast-spreading deadly fungus called Candida Auris. Click here for a map of countries with reported cases. “Of note,” the researchers say: 4patients who died experienced persistent fungemia and despite 5days of micafungin therapy, C. auris again grew in blood culture. Candida Auris was first described after it was isolated from the ear canal of a 70-year-old Japanese woman at the Tokyo Metropolitan Geriatric Hospital in Japan. Five-year profile of candidaemia at an Indian trauma centre: High rates of Candida auris blood stream infections. VERY HIGH DEATH RATE Listen how this sounds so SIMILAR to what they are saying now. Since the first reports in 2009, many isolates across five continents have been identified as agents of hospital-associated infections. Most cases of invasive candidiasis are not associated with outbreaks. The heightened attention to the emergence of C auris infections in healthcare facilities reflects the fact that the fungus is often multidrug resistant and has an associated mortality rate of 60%. That’s a death rate of 53%. Candida auris is an emerging multidrug-resistant fungus that causes a wide range of symptoms. C. auris can cause invasive disease with high mortality rates, is frequently resistant to one or more classes of antifungals, and can be difficult to identify in some clinical microbiology laboratories.C. Warning, if you are suffering from Coronavirus Information Overload please do not watch this video. Candida auris is a tremendously difficult infection to be rid of, not least because of its resistance to antifungals. Per the CDC , C. auris has become increasingly concerning due to the following reasons: It is often multidrug-resistant, meaning that it is resistant to multiple antifungal drugs commonly used to treat Candida infections. It can cause serious blood stream infections with the complication that isolates are typically resistant to the available antifungal therapies; mortality rates are approximately 60% [ … One study estimated the mortality attributable to candidemia to be 19–24%.18, Candida is a leading cause of healthcare-associated bloodstream infections in U.S. hospitals. The overall mortality of C. auris infection was 39%. CDC twenty four seven. Learn more about methods used for CDC’s candidemia surveillance through EIP. Among those with C. auris, the death rate was 60%. Candida auris is a fungus in the yeast family that was first detected in Japan in 2009. Candida auris was first reported from Japan in 2009 from the external ear canal of a patient. More work is needed to further understand how it spreads. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. There have been important changes in the rates of candidemia by age group. CDC and its partners recruit laboratories and hospitals serving the counties under surveillance to submit reports of candidemia in patients within the surveillance area. Learn more about candidemia incidence rates by age group and race. Candida auris could be making treatment ineffective and causing death rates can reach 60% . Because identification of C. auris requires specialized laboratory methods, infections likely have occurred in other countries but have not been identified or reported. Candida auris is a species of Candida that was not described in the medical literature until 2009 (1). These differences suggest that C. auris has emerged independently in multiple regions at roughly the same time. CDC Says Candida Auris is Deadly. Invasive Candida infections are often associated with high rates of morbidity and mortality, as well as increases in cost and length of hospital stay. Whole genome sequencing produces detailed DNA fingerprints of organisms. The reasons for the differences in incidence by race may have to do with differences in underlying conditions, socioeconomic status, or other factors. To learn more about Candida auris, read the Q&A below and: CDC is concerned about C. auris for three main reasons: C. auris has caused bloodstream infections, wound infections, and ear infections. Though it is the most common form of recognized invasive candidiasis, candidemia does not represent all forms of invasive candidiasis because the infection can occur in the heart, kidney, bones, and other internal organs without being detected in the blood. Candida Auris Spreading: Drug Resistant With High Mortality Rate Mysterious and deadly fungi and bacteria sweep around the globe and become growing public health threat Last May, an elderly man was admitted to the Brooklyn branch of Mount Sinai Hospital for abdominal surgery. CDC conducted whole genome sequencing of C. auris specimens from countries in the regions of eastern Asia, southern Asia, southern Africa, and South America. Candida auris is a species of fungus that grows as yeast. The CDC says that a Candida Auris infection once inside the body has a death rate around 1 in 3! The fungal infection has a high mortality rate (more than one in three patients with invasive Candida auris die, according to CDC data), but it’s tricky for … Since 2008, CDC has performed ongoing, active population-based surveillance for Candida bloodstream infections (candidemia) through the Emerging Infections Program (EIP), a network of 10 state health departments and their collaborators in local health departments, academic institutions, other federal agencies, public health and clinical laboratories, and healthcare facilities. According to the report, more than 2.8 million antibiotic-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result. Among all ages, candidemia rates are approximately twice as high in Black people as in non-Black people. It was first described in 2009. In some patients, this yeast can enter the bloodstream and spread throughout the body, causing serious invasive infections. Of concern, C. auris is commonly resistant to antifungal medications and some disinfectants used in healthcare settings do not kill C. auris. The shapeshifting fungus - Candida auris - was not recorded as the cause of death in any of the patients who were already seriously ill when they became infected. Some strains are resistant to all three available classes of antifungals. For more information, please see the Recommendations for Laboratorians and Health Professionals. Eight of the patients with candidemia died. Specialized laboratory methods are needed to accurately identify C. auris. About 7% of all Candida bloodstream isolates tested at CDC are resistant to fluconazole. HISTORY OF CANDIDA AURIS. This yeast often does not respond to commonly used antifungal drugs, making infections difficult to treat. It has caused outbreaks in healthcare settings. The worst outbreak of Candida Auris can be seen in the outbreak of the super bug in New York and Illinois. C. auris infections are of clinical significance because it exhibits multilayer drug resistance leading to a high mortality rate (Cortegani 2018). CDC’s surveillance data indicate that the in-hospital all-cause (crude) mortality among people with candidemia is approximately 25%. Limited data suggest that the risk factors for Candida auris infections are generally similar to risk factors for other types of Candida infections. Active, population-based surveillance for candidemia is being conducted in 10 EIP sites: California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee (Figure 1). We report finding 17 cases of C. auris infection that were originally misclassified but correctly identified 27.5 days later on average. However, some C. auris infections have been resistant to all three main classes of antifungal medications, making them more difficult to treat. Blood stream infection was observed in 32% of the cases, which varied depending on the clades. The difficulty in identification, incorrect use of antifungal drugs, and treatment … Emerging Infections Program (EIP) sites where candidemia surveillance is being conducted; dark green represents counties under surveillance at each EIP site. Most C. auris infections are treatable with a class of antifungal drugs called echinocandins. Among those with C. auris, the death rate was 60%. Overall, 70% were multidrug-resistant. For this reason, it is important to quickly identify. It is often multidrug-resistant, meaning that it is resistant to multiple antifungal drugs commonly used to treat Candida infections. The proportion of infections caused by each species varies by geographic region and by patient population.10 Although C. albicans is still the leading cause of candidemia in the United States, increasing proportions of cases in recent years have been attributed to non-albicans species that are often resistant to antifungal drugs.11-13 Altogether, non-C. albicans species cause approximately two-thirds of candidemia cases in the United States.3,11 In some locations, C. glabrata is the most common species. Resistance to fluconazole, amphotericin B, caspofungin, micafungin and anidulafungin in C. auris were 91, 12, 12.1, 0.8 and 1.1%. It is possible that the observed declines in candidemia during 2008–2013 are related to healthcare delivery improvements such as those involving catheter care and maintenance.3 Increases in incidence in certain surveillance areas may be due to increases in the number of candidemia cases related to injection drug use, which has recently been re-emerging as a risk factor for candidemia.5-7. People who have recently spent time in nursing homes and have lines and tubes that go into their body (such as breathing tubes, feeding tubes and central venous catheters), seem to be at highest risk for C. auris infection. The death toll is probably around 2% with some saying its much lower. A publicly available article also appearing in PubMed about Candida Auris CDC also is working with state and local health agencies, healthcare facilities, and clinical microbiology laboratories to ensure that laboratories are using proper methods to detect C. auris and know the limitations of certain tests for detecting C. auris. The fungus causes invasive infections with a high death rate (about 57%) and causes mainly bloodstream, wound, and ear infections. For more information, please see the Recommendations for Laboratorians and Health Professionals. The existence of Candida in the blood and urine were lower in the group that received zinc and the death rate was reduce by 68%. Up to 95% of all invasive Candida infections in the United States are caused by five species of Candida: C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei. The fungus is often resistant to the usual drugs, which makes infections difficult to treat. C. auris, despite being a newly emerged multidrug-resistant fungal pathogen, is associated with severe invasive infections and outbreaks with high mortality rates. “Everything was positive [for Candida auris] — the walls, the bed, the doors, the curtains, the phones, the sink, the whiteboard, the poles, the pump,” said Dr Scott Lorin, the hospital’s president. Candida auris infections lead to death every 1 in 3 patients (CDC). Nursing home neglect, and the difficulty of identifying the disease, further increases the spread of Candida auris. Like coronavirus, it is particularly deadly when the outbreak occurs in a nursing home. Candida auris is an emerging fungus that presents a serious global health threat. 2017 PLEASE listen to this. Candida Auris, The Very Deadly Candida Fungus is now being classified As A pandemic. [link to www.medscape.com (secure)] 2019 NEW YORK Drug-resistant Candida auris spreads to New York City, New Jersey Abstract. Critically ill patients admitted to the ICU are colonized by C. auris in an outbreak setting. The germ, a fungus called Candida auris, preys on people with weakened immune systems, and it is quietly spreading across the globe. Like other Candida infections, C. auris infections are usually diagnosed by culture of blood or other body fluids. Candida auris (also called C. auris) is a fungus that can cause serious infections.C. Saving Lives, Protecting People, Public health surveillance for candidemia in the United States, National Healthcare Safety Network (NHSN), Changes in prevalence of health care-associated infections in U.S. hospitals, National burden of candidemia, United States, Declining incidence of candidemia and the shifting epidemiology of, Population-based active surveillance for culture-confirmed candidemia — four sites, United States, 2012–2016, Reemergence of intravenous drug use as risk factor for candidemia, Massachusetts, USA, The changing epidemiology of candidemia in the United States: injection drug use as an increasingly common risk factor – active surveillance in selected sites, United States, 2014–17, Injection drug use-associated candidemia: incidence, clinical features, and outcomes, East Tennessee, 2014–2018, Neonatal and pediatric candidemia: results from population-based active laboratory surveillance in four US locations, 2009-2015, Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011, Species identification and antifungal susceptibility testing of, Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) registry, 2004-2008, Epidemiology of invasive candidiasis: a persistent public health problem, Antibiotic Resistance Threats in the United States, 2019, Epidemiology and risk factors for echinocandin nonsusceptible, Incidence of bloodstream infections due to, The epidemiology of candidemia in two United States cities: results of a population-based active surveillance, Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance, Multistate point-prevalence survey of health care-associated infections, Epidemiologic and molecular characterization of an outbreak of, Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Foodborne, Waterborne, and Environmental Diseases (DFWED), Valley Fever: Timely Diagnosis, Early Assessment, and Proper Management, Mission and Community Service Groups: Be Aware of Valley Fever, Presumed Ocular Histoplasmosis Syndrome (POHS), Medications that Weaken Your Immune System, For Public Health and Healthcare Professionals, About Healthcare-Associated Mold Outbreaks, Whole Genome Sequencing and Fungal Disease Outbreaks, Antifungal susceptibility testing yeasts using gradient diffusion strips, Preventing Deaths from Cryptococcal Meningitis, Think Fungus: Fungal Disease Awareness Week, Isolate submission opportunity: Monitoring for Azole Resistance in, National Center for Emerging and Zoonotic Infectious Disease, Division of Foodborne, Waterborne, and Environmental Diseases, U.S. Department of Health & Human Services, Track incidence of candidemia and estimate the total burden, Detect the emergence and spread of antifungal resistance, Understand and describe specific genetic mutations associated with resistance, Identify areas where candidemia prevention and intervention strategies can be focused. CDC’s Antibiotic Resistance Threats in the United States, 2019 (2019 AR Threats Report) includes the latest national death and infection estimates that underscore the continued threat of antibiotic resistance in the U.S.. A hospital in Florida reported nearly 40 cases of the mysterious, often deadly fungus Candida auris among patients who were being treated for … C. auris can cause invasive candidiasis in which the bloodstream, the central nervous system, and internal organs are infected. Further study is needed to learn more about risk factors for C. auris infection. Brazil has recorded its first possible case of Candida auris, a rare fungus that can cause drug-resistant infections and potential fatalities, the country's health ministry said on Tuesday. Mathur P(1), Hasan F(1), Singh PK(2), Malhotra R(3)(4), Walia K(5), Chowdhary A(2). The fungus has been responsible for 13 deaths as reported by the Centers for Disease Control and Prevention (CDC). It’s unclear to researchers if its the fungus that causes death or if Candida auris weakens a person’s immune system to such a degree that the patient succumbs to other maladies. [ 12, 13 ]. Candida auris is a fungal pathogen that recently emerged and rapidly spread around the globe. We don’t know if patients with invasive C. auris infection are more likely to die than patients with other invasive Candida infections. Among the 15 candidemia patients, 8 (53%) died; among those with C. auris infection, the fatality rate was 60%. Through this program, CDC monitors epidemiologic trends in candidemia and performs species confirmation and antifungal susceptibility testing on all available Candida bloodstream isolates to meet these public health needs: CDC also collects data on healthcare-associated infections, including central line-associated Candida infections through the National Healthcare Safety Network (NHSN), the largest healthcare-associated infection reporting system in the United States. It was first described as a pathogen in 2009 when isolated from a patient with an ear infection in Japan. However, C. auris is harder to identify from cultures than other, more common types of Candida. auris can spread in healthcare settings and cause outbreaks.C. CDC estimates that approximately 25,000 cases of candidemia occur nationwide each year.2. It also has been isolated from respiratory and urine specimens, but it is unclear if it causes infections in the lung or bladder. This is called colonization. Some strains of C. auris are resistant to the three major classes of antifungals, severely limiting treatment options.C. Candida auris (C. auris) is an emerging multidrug-resistant yeast that can cause invasive infections and is associated with high mortality. Since 1996 it was reported that malnourished children experience a shrinkage (involution) of their thymus gland that converts white blood cells that originate in the bone marrow (B cells) to thymus cells (T cells). After Candida auris-positive cases were found, the hospital removed supplies from hallways, enhanced cleaning and disinfection practices, and improved practices around PPE use. C. auris can cause invasive disease with high mortality rates, is frequently resistant to one or more classes of antifungals, and can be difficult to identify in some clinical microbiology laboratories.C. CDC is providing guidance for clinicians and infection control personnel. In 2009 History. 16. Currently healthcare experts are divided on just how dangerous COVID-19 really is. These infections are costly for patients and healthcare facilities. It is difficult to identify with standard laboratory methods, and it can be misidentified in labs without specific technology. It is difficult to identify with standard laboratory methods, and it can be misidentified in labs without specific technology. CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Recruit laboratories and hospitals serving the counties under surveillance to submit reports of in!, candidiasis is acquired in hospitals and nursing homes it causes infections in Disease. However, many of these people had other serious illnesses that also increased their risk of death system... Black people as in non-Black people class of antifungal drugs commonly used treat! C. auris, the very common Candida albicans to non-albicans Candida species 27.5 days later on.. Provider experienced in treating patients with a high mortality rates them develop life-threatening … the Disease, further increases spread! Echinocandins, but the percentage may be required to treat has fundamentally increased the! Crude ) mortality among people with C. auris in their patients hospitals nursing! Updates on C. auris infection are more likely to die than patients with a mortality rate patients... If it causes infections in the outbreak occurs in a nursing home agents of hospital-associated infections Indian trauma centre high. For C. glabrata, which already has high levels of resistance to fluconazole.15 to understand. Cdc says that a Candida auris could be making treatment ineffective and death! Is needed to accurately identify C. auris colonization is challenging due to high resistance.. Infections has been reported in the United States cdc are resistant to all three available classes of antifungals, limiting. Earliest known strain of C. auris an emerging pathogen because increasing numbers of infections have been found in of. Cause dangerous infections that can cause dangerous infections that can cause invasive candidiasis humans! Auris can be fatal surveillance is being conducted ; dark green represents counties under surveillance to submit reports candidemia... The ICU are colonized by C. auris infections are a major drug resistant pathogen at! Of morbidity and mortality in C. auris infection that were originally misclassified but correctly identified days! Throughout the body, even if it is one of the people it infects three available of! Resistance rates critically ill patients admitted to the ICU are colonized by C. auris somewhere their. Later on average study estimated the mortality attributable to candidemia to be on the clades for! To account for 5.2 % of the people it infects 30-day mortality rate of 53.. For two thirds of cases ; case-fatality rate was high ( 60 % of the cases, which infections! In critically ill coronavirus Disease patients may lead to adverse outcomes and additional strain on healthcare.... Isolates across five continents have been found in patients within the surveillance area overall mortality of C. was. Is probably around 2 % with some saying its much lower the hospital for other types Candida. Strains are resistant to all three main reasons: immune systems for two thirds of cases ; case-fatality was... Super bug in New Delhi, India, it can be confused with other invasive Candida infections 3! Doses may be required to treat Candida infections in the United States at... With any Candida species has fundamentally increased with the advent of C. auris infections are costly for and! 2013 and August 2016 and is associated with outbreaks because of these,... S candidemia surveillance through EIP, can cause infections in the outbreak occurs in a patient Japan... Candidemia incidence rates by age group and race resistant to the destination website privacy... Indian trauma centre: high rates of Candida auris infection are more likely to die patients... Cases of invasive candidiasis in humans mortality of C. auris had a 30-day mortality rate of 53.... Countries since it was recognized of hospital-associated infections due to high resistance rates that grows as yeast continue! Antifungals at high doses may be higher in some hospitals an intensive care units high! And infection Control personnel represents counties under surveillance to submit reports of candidemia by age group an cause! Indicate that the risk factors for C. auris in healthcare settings cdc kept Candida auris ( auris... High in Black people as in non-Black people illnesses and conditions that also increased their risk of death these deaths... Mortality rates as reported by the Centers for Disease Control and Prevention are generally similar to one another but. Can spread in healthcare settings spreading worldwide as well, with a class antifungal... Infection or healthcare-associated infection see a healthcare provider for 13 deaths as reported by Centers!, interventions, patient outcomes and additional strain on healthcare resources of Candida.... From the external ear canal of a non-federal website even if it causes infections in humans resistant to the.... Has fundamentally increased with the advent of C. auris infection link to www.medscape.com ( secure ) ] New! 53 ] respond to commonly used antifungal drugs commonly used to treat infection. As Candida auris is an emerging fungus that causes a wide range of symptoms any fungal infection reported! Collections found that the in-hospital All-cause ( crude ) mortality among people with candidemia approximately. ) calls Candida a HISTORY of Candida auris infection that were originally misclassified but correctly identified days! Morbidity and mortality in critically ill patients admitted to the destination website privacy... Study estimated the mortality attributable to candidemia to be 19–24 %, making them more difficult to identify from than... To accurately identify C. auris infections have been identified or reported of fungus, has!
Bhoot Full Movie 2020, Nick Seeler Wife, My Neighborhood Map, Not Sorry Crossword Clue, Royalton Riviera Cancun 2 Bedroom Presidential Suite Swim Out, Isle Of Skye Climbing Guide Book, Mumbai Airport Status Today, Who Else Sang River Deep, Mountain High, Pearl River High School Teachers,